Member Info for sadoldgit

Wishing you well Warty and a speedy recovery, it will take time of course.

Keep us updated here.

Regards

Jeez cobalt all it requires is 29 other people like myself who have applied for shares

Give Sareum their due they have made this option open to current shareholders.

What value would you place should 1801 prove superior to Deucravacitinib?

It will be better in Psoriasis, of that l have the upmost confidence

Tbc123

Good RNS, but you have eclipsed that by stating you are not going to.post again.

TTFN

Puma l have never done 10,000 words a day you soppy little sod.

Grow up and get a life, you are clearly rattled.

Seek comfort over on ADVN.

You posted over 120 time pleading with people to sell.

Sareum have not gone bust despite the efforts of people like you. (At least 2 on ADVN)

Go over and chat to them.

You tried your best but alas you have failed. Clearly your best not good enough.

Now run along and be a nice little boy for mummy or you will.not get your Easter egg.

You are correct MegRS300.

Identical agendas to one or two here.

300k is not much to raise.

Will be eaten up.

The good thing is 1801 is progressing.

I believe we are better than most of the others and that includes Deucravacitinib.

Regards and have a great Easter weekend.

Good evening 007,

Very little movement I perceive, prolific share dumping by RF will dry up soon.

No fears of getting to end of phase 1 a and data

Rise on data results and more on progress to phase 2,

On licence early phase 2 l would hazard a good guess.

Sp been hammered before RF came aboard and decimated afterwards.

9 million market cap on a company which its lead compound is now in clinical trial dnd yet 3 years ago circa 300 million.

Market sentiment!

I have an application for shares but l reckon will get nowhere near what l applied for.

To the relief of some will not be posting for bit but will let you know if my application amount gets met. Tis only 300k worth of shares

.

Regards

Who hates Puma.

If l do not agree with a person's argument does not mean l hate them.

You appear very similar to Puma.

Pop over to ADVN and have a read there and you will realise what hatred is.

Let me know what you think of a couple of the posters.

TTFN

Arrogance TBC 123

You need take a look at a few of Pumas posts.

In effect it is you thst started the stack aimed at myself.

Why dont you go over to ADVN and post your views over there if you are not already doing so?

I am sure they would welcome you.

Claimed to have been here years and made 4 posts in past few days supporting the derampers and how you should have listened to then.

Why didn't you sell 7 months ago?

Regards

Forgot to add

See no reason as to why we cannot go straight to phase 2.

Safety profile established.

MTD has not been established and in this event it is not unusual to accept dose 30x treatment dose which Sareum did with no dose limiting issues.

Phase 2 not a problem but will be costlier than phase1b due to patient involvement and increased time span.

Phase 2 will certainly add more meat on the bone and l would take a guess 1801 will be on licenced during this stage or maybe company takeover.

Regards

Good evening HbD, fully concur with what you say.

Tim.and Co will know more than we do. Thst will have latest data. Maybe the data so far has exceeded their expectations.

We are after all dual inhibition and no serious adverse events so far.

Attention to detail and getting things right will eventually pay off.

Regards

'They found that the probability of success was 63% in Phase I trials, 31% in Phase II trials, 58% in Phase III trials and 85% during the regulatory review process, for an overall success rate of 9.6% (63% × 31% × 58% × 85% = 9.6%).30 Jun 2016.'

Interesting Sareum are going for a phase2 and not 1b.

Involves more patients and hence more indicative of effectiveness in the indication in clinical study.

Much more meat on the bones with their intent to follow this route.

From 12 patients original intent with phase2 typically involving a couple of hundred.

My opinion here has not changed one iota in that we will better Deucravacitinib in Psoriasis.

Tom and Co clearly are confident in 1801.

Those that were predicting Sareum going into administration or the SP going to 1p on share dilution are a magnitude of order out.

There were those that wanted Sareum to collapse. Some will be disappointed with this.

Now ask yourselves a question.

Where would Sareum be if investors here sold all their shares 7 months ago?

I doubt Sareum would have been able to raise any funds at all and there would be many ie the last to leave that would own shares worth nothing.

Fortunately this did not play out.

We can now look forward to substantial increase in share value on good development news.

Nigh 20k invested by the BoD of which Parker will get 10k through WRAP.

I have put an application in but l along with others believe this will be over subscribed.

I will know next Wednesday should l not be allocated the amount l have supplied for.

I don't think l will get anywhere near 50k shares and that being very much less than supplied for.

Puma unfortunately sonny you will not be able to participate in this.

Overall the RNS's are good.

It allows us to progress 1801 without restraint.

Yippee

Onwards and upwards.

Completed share offer application via HL so have a decent sized order in, have a feeling they will be oversubscribed.

Closed Friday and Monday so not a lot of time.

If you are not fast you will be last.

Regards to all LTH

Hood.

'I hope you aren’t naive enough to truly believe that by banging on about how amazing the science is, readers won’t buy more shares.'

People still buy whether they read my posts or not.

How many people do you think you have taken your advice and sold and how many have not bought shares to you constant forecast of doom?

You make a statement that Sareum.need to raise money to continue trials.

On reality they only need for phase 1b which is around 6 months.

How can you make such a bold statement then admit you know nothing of the science, ie compounds potential worth and importance of data.

That best laugh of the day. Go and play with your buddies over on ADVN.

You must be their mouthpiece as they are inadequate to post on here.

Night night and be very careful.with that bow and arrow sonny.

The Hood does not care, as the Hood will fail to accept facts that either he cannot grasp or refuses to so as to support his own agenda.

Where have l led people?

Never once have l advised people to buy, as l am in no position to advise.

You have advised repetitively that people sell.

This is a fact.

I am here to see a compound on licenced or maybe a buyout before l sell heavily.

That is where the value lies.

I remember the Puma posting about Majwand.

His plan is to short the share then when it reaches its bottom, buy in and make whoosh loads of money on the rise.

You have the same plan.

I do believe that our real biggy in the bag is SDC1802. I am entirely in xgreement that we may have to give some of our ownership away on this one.

Potentially capable of 1 billion plus at late stage but a substantial amount of this may well be lost should we get involved in a partnership of some sort.

My belief is that Sareum had this as an option but deciding that this amount of loss could be removed by RF finance.

Ok if the SP remained high but as we can see not so good if it does not.

Regards

Price dependant on data results that will include biomarker data that will indicate areas that SDC1801 would be likely to show most potential.

Yes there are other inhibitors. Similar Tyk2 and Jak1 inhibitors,

They are not all the same. Breprocitinib has around similar selectivity for Tyk2 over Jak1

Molecular size being very important.

I have discussed this much in the past.

Our Molecules all 31 0f them are patented.

The compounds as they sat during candidate selection, preclinical evaluation at end of preclinical, phase 1a, phase lb and the price would rise considerably from.the previous stage.

Indications as to which areas of therapy gained on phase1a data along with biomarker data will indicate areas of greatest potential for market commercialisation.

Regards

On satisfactory safety data, SDC 1802 can enter phase 2 trials. Does the Hood accept this fact or disagree and if so on what basis would you make your argument?

Would the Hood care to place a value on the worth of this compound alone accepting the fact that we will have a compound SDC that can enter phase2 straight from end of preclinical?

Regards

Never been a Mr Orange on here!

The value at the time?

You have little to know knowledge of Sareum or the rorth or potential wort of either SDC1801 or SDC1802.

The value will rise considerably from end of preclinical to end of phase1.

Clearly you are out of your depth here.

Data results are what are required by the interested parties as stated in the 2022 AGM.

'WELL SHOW US SOME DATA'

Do you remember this or are you as l believe you are ignorant of this fact also?

Regards